Clinical Trial: CBD Administration Reduces Heroin Cravings

Generic 22 May 2019 | 0 Comments

The administration of oral CBD reduces cue-induced cravings and anxiety in subjects with a history of heroin use, according to clinical data published in The American Journal of Psychiatry.

Investigators at The Mount Sinai Health System in New York City assessed the effect of CBD versus placebo in 42 drug-abstinent participants with a history of heroin use. In contrast to placebo, CBD dosing of either 400mg or 800mg “significantly reduced both the craving and anxiety induced by drug cues … in the acute term. CBD also showed significant protracted effects on these measures seven days after the final short-term exposure.”

Researchers concluded, “CBD’s potential to reduce cue-induced craving and anxiety provides a strong basis for further investigation of this phytocannabinoid as a treatment option for opioid use disorder.”

In observational models, patients with legal access to cannabis typically reduce or eliminate their use of opioids. In clinical models, CBD administration has been shown to reduce cravings for tobacco. CBD dosing has also been associated with reduced cravings for methamphetamine in preclinical models.

Commenting on the study’s findings, NORML Deputy Director Paul Armentano said, “These conclusions add to the growing body of evidence that cannabis and its constituents represent an exit away from the use or abuse of other controlled substances rather than a supposed ‘gateway.’”

The abstract of the study, “Cannabidiol for the reduction of cue-induced craving and anxiety in drug-abstinent individuals with heroin use disorder: A double-blind randomized placebo controlled trial,” appears online here. Additional information is available in NORML’s fact-sheet, “Relationship between marijuana and opioids.”

Tagged in , ,

CBD clinical trial results on seizure frequency in dogs ‘encouraging’

Did you know that? 21 May 2019 | 0 Comments

Scientists have found in a small study that 89 percent of dogs who received CBD in the clinical trial had a reduction in the frequency of seizures. Nine dogs were treated with CBD, while seven in a control group were treated with a placebo.

Tagged in

Nevada: Reform Efforts are Still Alive

Generic 21 May 2019 | 0 Comments

Even though cannabis has been recreationally legal in the Battle Born State for nearly two years and Sin City has become a greenish gold mine of legal cannabis, many problems and societal penalties still arise with the use of it; no social consumption lounges being among the most glaring. Yet unlike the consumption lounges, people’s lives are directly being negatively impacted by laws surrounding pre-employment drug testing and previous cannabis convictions in the Prohibition years.

Assembly Bill 132, a bill still being discussed in the Nevada Legislature, could benefit medical patients across the state from employment discrimination simply because they test positive for cannabis. Whereas a marijuana-positive drug test from an applicant would likely mean more immediate professional rejection than showing up to an interview in a neon bro tank and American flag Chubbies, AB 132 would provide cannabis users with a rebuttal if a pre-employment drug test is failed.

Quoted exactly, the bill authorizes “an employee to rebut the results of a screening test under certain circumstances; creating a presumption that the ability of an employee to perform his or her job and that the safety of other employees is not adversely affected if an employee has certain levels of certain prohibited substances in his or her blood.”              

Without exception, The War on Drugs was a bigger critical failure than Fyre Festival could’ve ever dreamed about. Millions now carry harmful convictions for harmless offenses that still haunt their lives and deeply hinder their access to everything from housing, financial assistance and employment opportunities. Even if they aren’t drug-related, a misdemeanor conviction can still have drastic social consequences.

Partially as a legislative apology for the frivolous and unnecessary wrongs of the War on Drugs and partially to boost possible employment opportunities to past “offenders”, Assembly Bill 192 would create a program for anyone with permanent criminal charges to apply for the records of those crimes to be sealed. While this bill certainly applies to the unfortunately large demographic of people who have low-level cannabis charges, AB 192 applies concurrently to other charges that once were illegal in Nevada but have been decriminalized through either prior or current legislation.

Medical marijuanaAnother frank reality of medical cannabis in modern America, apart from the increase of Taco Bell consumption, is the mountains of research behind the number of conditions that the plant treats. PTSD, cachexia and muscle spasms are among the nearly never ending list of conditions that cannabis has been proven to treat in most cases. With Nevada Senate Bill 430, the list of qualifying conditions would be expanded dramatically with specific wordings in the bill to define which condition could legally be treated with medical cannabis. With the broadening power of SB 430, conditions from anxiety and AIDS to cancer and opioid dependency would be considered qualifying conditions by the Silver State, greatly expanding the spectrum of conditions eligible for medical cannabis from the currently extremely restrictive list.

The aforementioned bills could be historic for the constantly debated subject of cannabis patient rights and would have an extremely positive impact for both medical and recreational cannabis users alike and would surely lead to further de-stigmatization and medical cannabis patient reform that is leaps and bounds ahead of states that subscribe to stricter cannabis-related policies.

As there’s still a small window of time in the Nevada Legislature’s 2019 session, now is the appropriate time to contact your respective representative and let your voice be heard. Please visit NORML’s Action Center at https://norml.org/act for information on specific bills.

Tagged in , , ,

Massachusetts: State Regulators Grant Initial Approval To Social Use Spaces

Generic 20 May 2019 | 0 Comments

Members of the state’s Cannabis Control Commission have decided to advance plans to regulate social marijuana use facilities.

Regulators voted 3 to 2 in favor of the proposal, which seeks to establish a pilot program in up to a dozen self-selected cities throughout the state. However, implementing the plan will require additional legislative action from lawmakers.

To date, only Alaska has enacted statewide regulations governing on-site marijuana consumption sites. Similar legislation to establish “marijuana hospitality spaces” is before the Governor of Colorado. Earlier this month, city officials in Las Vegas approved a municipal ordinance to license on-site consumption spaces.

Tagged in ,

NORML Submits Comments to FDA Ahead of CBD Hearing

Generic 16 May 2019 | 0 Comments

Marijuana CBD OilNORML has submitted written comments to the US Food and Drug Administration ahead of the agency’s scheduled hearing on the regulation CBD-infused products. The agency will be taking in person public testimony on Friday, May 31, with regard to the “manufacturing, product quality, marketing, labeling, and sale” of CBD-infused retail products.

In its written testimony, NORML encourages the FDA to act expeditiously to clarify confusion among both consumers and regulators with regard to the legality of specific CBD products. It further recommends that the FDA provide regulatory guidelines governing product manufacturing, standardization, and quality.

Currently, commercially marketed CBD-infused products are not subject to explicit federal regulations. As a result, third-party lab testing has frequently revealed inconsistencies between the percentage of CBD advertised and the amount actually contained in the product. In many cases — such as those reported here, here, here, here, and here — actual quantities of CBD in the product is far lower than advertised. In other cases, testing has revealed the presence of THC, which may put consumers in jeopardy for legal ramifications – such as arrest or the loss of employment (due to a drug test failure). Some commercial products have also been identified to contain unwanted and potentially dangerous adulterants – such as 5F-ADB (aka ‘Spice’) or DXM – as well as heavy metals and solvents.

NORML’s testimony concluded: “For years, producers of these products have navigated in a grey area of the law — manufacturing products of variable and sometimes questionable quality and safety. Now it is time for the FDA to craft benchmark safety and quality standards for hemp-derived CBD products in order to increase consumer satisfaction and confidence as this nascent industry transitions and matures into a legal marketplace.”

The FDA is accepting written comments from the public through July 2, 2019.

In December, Congress enacted legislation removing industrial hemp (defined as cannabis containing less than 0.3 percent THC) and products containing cannabinoids derived from hemp from the federal Controlled Substances Act. The following day, the FDA stated: “Congress explicitly preserved the agency’s current authority to regulate products containing cannabis or cannabis-derived compounds under the Federal Food, Drug, and Cosmetic Act (FD&C Act) and section 351 of the Public Health Service Act.” The agency further opined, “[I]t’s unlawful under the FD&C Act to introduce food containing added CBD or THC into interstate commerce, or to market CBD or THC products as, or in, dietary supplements, regardless of whether the substances are hemp-derived.”

In March, outgoing FDA Commissioner Scott Gottlieb suggested that it may take “years” for the agency to establish rules and regulations governing the marketing of hemp-derived cannabinoid products.

Tagged in , , ,